Attorney Docket No. 5146

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rudolph, et al.

Serial No.: 10/719,485

Title: Anilinopyrazole Derivatives Useful for the Treatment of Diabetes

MAIL STOP PATENT APPLICATION COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449.

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

## **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-6450

Facsimile: (203) 812-6459

	Form PTO (Modified)		U.S. Department of Commerce Patent and Trademark Office							Serial No.	Art Unit	"		Atty. Docl			
	L								}	10/719,485 Applicant(s)	1614	11/21	1/03	5146	<u> </u>		
TPE	INFORMATION DISCLOSURE CITATION									Rudolph, et al.							
	(S)		Audorphi, or un														
N 10	004								S. PA	TENT DOCU	MENTS						
N 10	500		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE			
		U1	5 9 9 8 4 2 4						4	12/07/99			-				
		U2	5	9	1	6	9	0	8	06/29/99							
		U3	5	9	4	2	5	2	0	08/24/99							
		U4	3	7	9	0	5	7	6	02/05/74							
									<u> </u>					ļ			
											<u> </u>						
				ļ					<u> </u>	1	<del></del>			<u> </u>			
	FOREIGN PATENT DOCUMENTS																
	*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSI	LATION NO		
		F1	9	6	1	4	8	4	3	23/05/96	WO						
		F2	1	1	4	3	5	.1	5	14/02/63	DE	ï					
		F3	9	7	0	8	1	4	9	06/03/97	WO						
		F4	9	3	1	9	0	5	4	30/09/93	WO						
					ļ	ļ											
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)																
		R1	Menzel, et al., "Synthesen und Reaktionen neuer ortho-kondensierter Pyrazoloverbindungen," Angew. Chem., <u>74 (21)</u> 839-847 (1962).														
		R2	Crenshaw, et al., "Interferon Inducing Activities of Derivatives of 1,3-Dimethyl-4-(3-dimethylaminopropylamino)-1 <i>H</i> -pyrazolo[3,4- <i>b</i> ]quinoline and Related Compounds," J. Med. Chem, 19(2), 262-275 (1976).														
		R3	Catarzi, et al., "Tricyclic Heteroaromatic Systems. Synthesis and A <sub>1</sub> and A <sub>2a</sub> Adenosine Binding Activities of Some 1-Aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c]pyrazol-4-ones,1-Aryl-4,9-dihydro-3-methyl-1 <i>H</i> -pyrazolo[3,4-														
			b]quinolin-4-ones, and 1-Aryl-1 <i>H</i> -imidazo[4,5- <i>b</i> ]quinoxalines," J. Med. Chem., <u>38</u> , 1330-1336 (1995).														
														<u></u>			
	1																
		1															